Bedaquiline

Chemical formula: C₃₂H₃₁BrN₂O₂ Molecular mass: 555.505 g/mol PubChem compound: 5388906

Therapeutic indications

Bedaquiline is indicated for:

Pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Bedaquiline is indicated for use as part of an appropriate combination regimen in adult and paediatric patients (2 years to less than 18 years of age and weighing at least 7 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampicin and isoniazid.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

400 mg once daily at Weeks 1-2 and thereafter 200 mg once daily 3 times per week at weeks 3-24

160-400 mg once daily at Weeks 1-2 and thereafter 80-200 mg 3 times per week at Weeks 3-24 based on body weight

Contraindications

Bedaquiline is contraindicated in the following cases:

Lactation

Severe hepatic impairment

Hepatic failure stage IV

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.